Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6-Reference-Cited by-同舟云学术

Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6

Published:2021 Issue:2 Volume:12 Page:178-196
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Chan Alexandria M.¹²³⁴,Fletcher Steven¹²³⁴⁵^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences

2. University of Maryland School of Pharmacy

3. Baltimore

4. USA

5. University of Maryland Greenebaum Cancer Center

Abstract

Exploiting the tolerance to variability in the capping group of HDAC inhibitors, pharmacophore grafting has spawned polypharmacological co-inhibitors of HDAC6.

Funder

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D0MD00286K

Reference148 articles.

1. Alarm activation, pattern discovery, and anomaly detection in sensor networks

2. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

3. HDACs and HDAC Inhibitors in Cancer Development and Therapy

4. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases

5. Histone deacetylase inhibitors: molecular mechanisms of action

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors;Bioorganic & Medicinal Chemistry;2024-04

2. A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds;Current Medicinal Chemistry;2023-10-19

3. Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation;Bioengineering & Translational Medicine;2023-10-14

4. Role of primary aging hallmarks in Alzheimer´s disease;Theranostics;2023

5. Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge;ACS Pharmacology & Translational Science;2022-10-10